Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

T cell differentiation is a progressive process characterized by phenotypic and functional changes. By transferring tumor-specific CD8+ T cells into tumor-bearing mice at various stages of differentiation, we evaluated their efficacy for adoptive immunotherapy. We found that administration of naive and early effector T cells, in combination with active immunization and IL-2, resulted in the eradication of large, established tumors. Despite enhanced in vitro antitumor properties, more-differentiated effector T cells were less effective for in vivo tumor treatment. Several events may underlie this paradoxical phenomenon: (a) downregulation of lymphoid-homing and costimulatory molecules; (b) inability to produce IL-2 and access homeostatic cytokines; and (c) entry into a proapoptotic and replicative senescent state. While the progressive acquisition of terminal effector properties is characterized by pronounced in vitro tumor killing, in vivo T cell activation, proliferation, and survival are progressively impaired. These findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy.

[1]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[2]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[3]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[4]  C. Klebanoff,et al.  Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1 , 2004, The Journal of Immunology.

[5]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[7]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[8]  T. Schumacher,et al.  Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation , 2004, The Journal of experimental medicine.

[9]  Victor Appay,et al.  Lessons from the study of T-cell differentiation in persistent human virus infection. , 2004, Seminars in immunology.

[10]  C. June,et al.  Extensive Replicative Capacity of Human Central Memory T Cells1 , 2004, The Journal of Immunology.

[11]  T. Rowley,et al.  Stimulation by Soluble CD70 Promotes Strong Primary and Secondary CD8+ Cytotoxic T Cell Responses In Vivo 1 , 2004, The Journal of Immunology.

[12]  Hermann Wagner,et al.  Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E John Wherry,et al.  The role of programming in memory T-cell development. , 2004, Current opinion in immunology.

[14]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[15]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Lefrançois,et al.  Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. , 2004, Blood.

[17]  Tao Dong,et al.  Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.

[18]  R. Childs,et al.  Nonmyeloablative allogeneic immunotherapy for solid tumors. , 2004, Annual review of medicine.

[19]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[20]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[21]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.

[22]  J. Borst,et al.  CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool , 2003, The Journal of experimental medicine.

[23]  Ulrich H. von Andrian,et al.  Homing and cellular traffic in lymph nodes , 2003, Nature Reviews Immunology.

[24]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[25]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[26]  Jonathan J. Lewis,et al.  A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1 , 2003, The Journal of Immunology.

[27]  G. Ferry,et al.  Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3* , 2003, The Journal of Biological Chemistry.

[28]  P. Marrack,et al.  T cell apoptosis and reactive oxygen species. , 2003, The Journal of clinical investigation.

[29]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[30]  F. Sallusto,et al.  Opinion-decision making in the immune system: Progressive differentiation and selection of the fittest in the immune response , 2002, Nature Reviews Immunology.

[31]  D. Voehringer,et al.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.

[32]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[34]  C. Hallahan,et al.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.

[35]  J. Sprent,et al.  Interleukin 15 Controls both Proliferation and Survival of a Subset of Memory-Phenotype CD8+ T Cells , 2002, The Journal of experimental medicine.

[36]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[37]  B. Gärtner,et al.  The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection , 2002, AIDS.

[38]  J. Sprent,et al.  Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.

[39]  C. Benoist,et al.  Cytokine Requirements for Acute and Basal Homeostatic Proliferation of Naive and Memory CD8+ T Cells , 2002, The Journal of experimental medicine.

[40]  E. Pamer,et al.  Homeostasis of naïve, effector and memory CD8 T cells. , 2002, Current opinion in immunology.

[41]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[42]  T. Waldmann,et al.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.

[43]  S. Rosenberg,et al.  Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity , 2001, The Journal of Immunology.

[44]  D. Voehringer,et al.  Viral Infections Induce Abundant Numbers of Senescent CD8 T Cells1 , 2001, The Journal of Immunology.

[45]  Wolfgang Weninger,et al.  Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.

[46]  J. Lieberman,et al.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. , 2001, The Journal of clinical investigation.

[47]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[48]  T. Schumacher,et al.  CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.

[49]  S. Jameson,et al.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.

[50]  J. R. Smith,et al.  Identification of a Gene That Reverses the Immortal Phenotype of a Subset of Cells and Is a Member of a Novel Family of Transcription Factor-Like Genes , 1999, Molecular and Cellular Biology.

[51]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[52]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[53]  J. Krauss,et al.  Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. , 1996, Cancer research.

[54]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.